feedback

Course Director

Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, MACP, FASCO

University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Faculty

William K. Oh
William K. Oh, MD

Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, New York

Evan Y. Yu
Evan Y. Yu, MD

University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, Washington

Accredited by

Purdue University College of Pharmacy

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2019-Mar-26
Expiration Date:2020-Mar-25
Estimated Time for Completion:1.5 hours
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings.

Upon completion of this activity, participants should be better able to:
  • Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer
  • Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment
  • Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences

Target Audience

This activity has been designed to meet the educational needs of medical and urologic oncologists, and other clinicians involved in the management of patients with prostate cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2019 - March 25, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Moderator

Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Exelixis, Inc.; F. Hoffmann-La Roche Ltd; and Seattle Genetics.
Advisory Board for Astellas Pharma US, Inc.; Eisai Inc; and Janssen Pharmaceuticals, Inc.

Faculty

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Deputy Director, Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, New York

William K. Oh, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bayer Corporation; CPS Companion Diagnostics; Janssen Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Sema4; TeneoBio; and Tyme Inc.

Evan Y. Yu, MD
Professor, Department of Medical Oncology
University of Washington School of Medicine
Medical Director, Clinical Research Support
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Evan Y. Yu, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Agensys; Dendreon Pharmaceuticals LLC; Merck & Co., Inc.; and Seattle Genetics, Inc.
Advisory Board for Amgen Inc.; AstraZeneca; Bayer Corporation; Dendreon Pharmaceuticals LLC; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics LLC; Seattle Genetics, Inc.; and QED Pharmaceutical Services.

Medical Directors

Hamsa Jaganathan, PhD
PVI, PeerView Institute for Medical Education

Hamsa Jaganathan, PhD, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support: Spouse is a consultant for Baxter, Becton Dickinson, and Sensyne Health.

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members and reviewers, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Clovis Oncology, Inc., Genomic Health Inc., and Sanofi Genzyme.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Purdue University College of Pharmacy are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Purdue University College of Pharmacy. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. For approved prescribing information, please consult the manufacturer's product labeling. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our activities. No responsibility is taken for errors or omissions in activities.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.